Evidence map›Paper›PMID 41123555›Full record

ArticleJournal of the Pediatric Infectious Diseases Society2025

Factors Associated With Newborn Nirsevimab Administration in Los Angeles County During the 2024 Respiratory Syncytial Virus Season.

Huan Vinh Dong, Neema Pithia, Choiyuk Chiang, Megan Halbrook, Melanie Barr, Sherry Yin, Adriana Diaz, James Beekley, Nava Yeganeh

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Pediatric Infectious Diseases Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Huan Vinh DongDivision of Pediatric Infectious Diseases, University of California, Los Angeles, Los Angeles, CA, United States.ORCID 0000-0002-6370-1811
Neema PithiaDivision of Pediatric Infectious Diseases, University of California, Los Angeles, Los Angeles, CA, United States.
Choiyuk ChiangVaccine Preventable Disease Control, Los Angeles County Department of Public Health, Los Angeles, CA, United States.
Megan HalbrookVaccine Preventable Disease Control, Los Angeles County Department of Public Health, Los Angeles, CA, United States.
Melanie BarrVaccine Preventable Disease Control, Los Angeles County Department of Public Health, Los Angeles, CA, United States.
Sherry YinVaccine Preventable Disease Control, Los Angeles County Department of Public Health, Los Angeles, CA, United States.
Adriana DiazVaccine Preventable Disease Control, Los Angeles County Department of Public Health, Los Angeles, CA, United States.
James BeekleyVaccine Preventable Disease Control, Los Angeles County Department of Public Health, Los Angeles, CA, United States.
Nava YeganehDivision of Pediatric Infectious Diseases, University of California, Los Angeles, Los Angeles, CA, United States.

Funding

Addressing Evolving Infectious ThreatsT32AI177290 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Risa M. Hoffman, Karin Nielsen · 2023 to 2026
$1.3M
NIAID NIH HHS T32 AI177290NIH HHS T32AI177290
6 · The paper itself

Abstract

Nirsevimab reduces respiratory syncytial virus-related hospitalizations and is recommended for infants shortly after birth during RSV season. We compared characteristics of newborns who received nirsevimab to those who received hepatitis B vaccine within one week of life to better identify gaps in coverage and target public health outreach. One year after the introduction of nirsevimab, fewer infants received the recommended birth dose of nirsevimab as compared to hepatitis B vaccine.

Indexed as

Antibodies, Monoclonal, HumanizedAntiviral AgentsRespiratory Syncytial Virus InfectionsFemaleHepatitis B VaccinesHumansInfantInfant, NewbornLos AngelesMaleSeasonsAntibodies, Monoclonal, HumanizedAntiviral AgentsHepatitis B Vaccineshealthy places indexhepatitis B vaccineneonatal immunizationsnirsevimabrespiratory syncytial virus

Identifiers

PMID41123555
PMCPMC12596719

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.